Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 8/20 | 0.45 |
| ▸ | METAP1 | P53582 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | CCR2 | P41597 | 3/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | DPEP1 | P16444 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12022078 | 1.00 | METAP2 (0.45) | METAP2METAP1SMN1; SMN2MAPTAAK1 | |
| SCHEMBL25856561 | 0.92 | ALDH1A1 (0.53) | METAP2METAP1SMN1; SMN2AAK1MEN1 | |
| SCHEMBL15199425 | 0.92 | ALDH1A1 (0.53) | METAP2METAP1SMN1; SMN2AAK1MEN1 | |
| SCHEMBL19254379 | 0.92 | METAP2 (0.44) | METAP2METAP1SMN1; SMN2MAPTAAK1 | |
| SCHEMBL14984996 | 0.89 | METAP2 (0.47) | METAP2METAP1MAPTAAK1MEN1 | |
| SCHEMBL21017154 | 0.87 | AAK1 (0.42) | METAP2METAP1SMN1; SMN2AAK1MEN1 | |
| SCHEMBL12022079 | 0.86 | EPHX2 (0.54) | METAP2METAP1MAPTMEN1ALDH1A1 | |
| SCHEMBL12022082 | 0.86 | METAP2 (0.57) | METAP2METAP1 | |
| SCHEMBL15199424 | 0.84 | NPC1 (0.46) | METAP2METAP1AAK1ALDH1A1GAA | |
| SCHEMBL18458473 | 0.84 | AAK1 (0.41) | METAP2METAP1AAK1MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230225996-A1 | BIOMARKERS OF METAP2 INHIBITORS AND APPLICATIONS THEREOF | SYNDEVRX, INC. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230225996-A1 | BIOMARKERS OF METAP2 INHIBITORS AND APPLICATIONS THEREOF | METAP2, METAP1, PEBP1 | METAP2 1/4885METAP1 2/4885SMN1; SMN2 2967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.